Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart software aims to sharpen heart valve treatment decisions

NCT ID NCT06392464

Knowledge-focused Sponsor: Dilemma Solutions S.L. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a computer program called naevia medical that helps doctors decide the best treatment for heart valve disease. Researchers looked at 106 past patient cases to see if the tool gave better recommendations than usual care. The goal was to see if the tool could reduce mistakes and improve patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

106 people

The number who actually took part.

Started

Mar 2024

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients evaluated in the outpatient clinic affected by heart valve disease

Ages

18 to 100 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients randomly selected from those presented during the year 2022 in medical-surgical sessions, with a primary diagnosis of: * aortic valve stenosis * aortic insufficiency * mitral valve stenosis * mitral insufficiency (greater than moderate severity).. * Patients randomly selected from valvulopathy clinic records attended during the year 2022, with a primary diagnosis of * aortic valve stenosis * aortic insufficiency * mitral valve stenosis * mitral insufficiency (greater than moderate severity) Exclusion Criteria: * Subjects under 18 years old. * Inability to anonymize the case. * Clinical cases of valvulopathies in which a complex congenital heart disease coexists. * Clinical cases that do not meet the minimum data set necessary for decision-making. * Clinical cases with a primary diagnosis other than valvulopathy. * Presence of bacterial endocarditis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic insufficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic valve insufficiency aortic valve stenosis heart valve disorder mitral valve insufficiency mitral valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart valve disease

Contacts and locations

Locations

  • Complejo Hospitalario Universitario de Santiago de Compostela

    Santiago de Compostela, 15701, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.